Target Information

Target General Infomation
Target ID
T40459
Former ID
TTDR00677
Target Name
Interleukin-13 receptor alpha-2 chain
Gene Name
IL13RA2
Synonyms
IL-13R alpha-2 chain; Interleukin-13 binding protein; IL13RA2
Target Type
Clinical Trial
Disease Asthma; Idiopathic pulmonary fibrosis; Alopecia areata; Ulcerative colitis; Atopic dermatitis [ICD10: J45, J84.1, K51, L20]
Brain cancer; Glioblastoma multiforme [ICD9:191, 225.0; ICD10: C71, D33]
Ulcerative colitis [ICD9: 556; ICD10: K51]
Function
Binds with low affinity to interleukin-13 (IL13). Together with IL4RA can form a functional receptor for IL13. Also serves as an alternate accessory protein to the common cytokine receptor gamma chain for interleukin-4 (IL4) signaling,but cannot replace the function of IL2RG in allowing enhanced interleukin-2 (IL2) binding activity.
BioChemical Class
Cytokine receptor
UniProt ID
Q14627
Sequence
MAFVCLAIGCLYTFLISTTFGCTSSSDTEIKVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
HFKECTVEYELKYRNIGSETWKTIITKNLHYKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNWQYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDFYICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCFDYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQCWEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Structure
3BPN; 3BPO; 4HWB; 3LB6
Drugs and Mode of Action
Drug(s) Tralokinumab Drug Info Phase 3 Ulcerative colitis [524980], [542917]
ICT-107 Drug Info Phase 2 Brain cancer; Glioblastoma multiforme [523325]
Tralokinumab Drug Info Phase 1/2 Asthma; Idiopathic pulmonary fibrosis; Alopecia areata; Ulcerative colitis; Atopic dermatitis [889368], [889371], [889374], [889376], [889391], [889408], [889414], [889420]
Modulator Tralokinumab Drug Info
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Jak-STAT signaling pathway
NetPath Pathway IL4 Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database IL4-mediated signaling events
References
Ref 523325ClinicalTrials.gov (NCT01280552) A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM). U.S. National Institutes of Health.
Ref 524980ClinicalTrials.gov (NCT02281357) Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With Oral Corticosteroid Dependent Asthma. U.S. National Institutes of Health.
Ref 542917(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8001).
Ref 889368ClinicalTrials.gov (NCT01402986) A Safety and Efficacy Study of Tralokinumab in Adults With Asthma
Ref 889371ClinicalTrials.gov (NCT01482884) Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis
Ref 889374ClinicalTrials.gov (NCT01592396) A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma
Ref 889376ClinicalTrials.gov (NCT01629667) A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Ref 889391ClinicalTrials.gov (NCT02085473) A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Tralokinumab When Delivered at Different Flow Rates to Healthy Volunteers
Ref 889408ClinicalTrials.gov (NCT02347176) Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis
Ref 889414ClinicalTrials.gov (NCT02449473) Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids
Ref 889420ClinicalTrials.gov (NCT02684097) A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
Ref 551019Clinical pipeline report, company report or official report of ImmunoCellular Therapeutics.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.